Trials / Completed
CompletedNCT02561962
A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma
A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 224 in Subjects With Relapsed or Refractory Multiple Myeloma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a first in human phase 1 multicenter open label study in subjects with relapsed or refractory multiple myeloma.
Detailed description
This is a first in human phase 1 multicenter open label study to evaluate the safety and tolerability of AMG 224 in subjects with relapsed or refractory multiple myeloma. The study will be conducted in 2 parts. Part 1 is the dose-exploration and part 2 is the dose-expansion. Study medication will be administered once every 3 weeks by intravenous (IV) infusion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 224 | Administered as an IV infusion. |
Timeline
- Start date
- 2015-11-20
- Primary completion
- 2018-11-30
- Completion
- 2022-04-21
- First posted
- 2015-09-28
- Last updated
- 2024-02-01
- Results posted
- 2021-10-07
Locations
5 sites across 2 countries: United States, Australia
Source: ClinicalTrials.gov record NCT02561962. Inclusion in this directory is not an endorsement.